CV Risk Profiles Before Chemotherapy minimize toxicity

This guidance overviews CV risk stratification prior to receiving certain cancer therapies to minimize the risk of CV toxicity from cancer treatments

Cardio-Oncology is the cardiac care of cancer patients. Cardiac issues may develop during cancer treatment or may be pre-existing or may develop as late effects. There has been increasing recognition of these issues recently which has led to the development of the new sub-specialty of Cardio-Oncology bringing together multidisciplinary teams of cardiologists, oncologists and allied healthcare professionals. This 45-minute webinar with 15-mins lives Q&A, presented by Dr Daniel Lenihan (Washington, US) and moderated by Dr Arjun Ghosh (Barts Heart Centre and UCLH, UK) is designed for those interested in learning about how to set up a brand new Cardio-Oncology service at their centre. Dr Daniel Lenihan, MD is a Cardio-Oncologist specializing in cardiology, heart disease and advanced heart failure. He has experience in developing Cardio-Oncology programs at both Vanderbilt in Nashville and Washington University. He is the current President of the International Cardio-Oncology Society. Dr Arjun Ghosh is a consultant cardiologist at Barts Heart Centre and UCLH. He helped establish Cardio-Oncology services at both hospitals and is the first cardiologist in the Uk appointed specifically in Cardio-Oncology.

Daniel Lenihan
Arjun K Ghosh

Cardio-Oncology Programs

In the rapidly changing world of healthcare, there is an obvious momentum to establish a Cardio-Oncology program at a variety of institutions or practices. Each medical provider location has its own unique resources with a variety of potential solutions. Dr Lenihan has developed robust Cardio-Oncology programs at 3 major institutions around the country and can provide extensive recommended solutions for any specific situation.

This webinar aims to help viewers:

Learning Objectives

  • Understand how specialised Cardio-Oncology services improve cancer and cardiac care for patients.
  • Understand the practicalities of setting up a Cardio-Oncology service.
  • Understand who the stakeholders are.
  • Understand the components of the service.
  • Understand where the funding comes from.

This webinar is aimed at:

Target Audience

  • Pharmacists working at DGHs and tertiary
  • Cardiologists
  • Medical and Clinical Oncologists
  • Cardiac and oncology specialist nurses
  • Haemato-oncologists
  • Trainees

Clinical practice principles that are essential to develop a vibrant Cardio-Oncology (C-0) program

  • Be intentional for establishing a strong clinical connection with oncology and hematology providers.
  • Forge an excellent working relationship with primary care and internal medicine providers who are likely to treat cancer survivors.
  • Identify key administrators and clinicians in each area and ensure that they realize the purpose and benefits of C-0 services.
  • Emphasize to all that optimal cardiovascular care for patients with cancer has a major positive clinical impact and is consistent with contemporary multidisciplinary care.

  • Explore outside your own institution to the surrounding communities and practices to identify potential referring providers.
  • Ascertain the best methods for communication among providers in order to become an essential part of the work flow.
  • Participate in multidisciplinary meetings (such as tumor boards, faculty meetings, or a “chemotherapy/cardiac safety” committee).
  • Openly discuss difficult cases in a collaborative forum that allows all providers involved to have access to the thought processes and decision-making.
  • Evaluate a patient’s eligibility to enroll in C-0 clinical trials

What do you need to develop a vibrant Cardio-Oncology Program?

Overview of the recent Centers of Excellence

A recent presentation by Drs Vijay Rao and Dan Lenihan provides an overview of the recent Centers of Excellence designation by IC-OS of leading institutions and programs around the world.


Developing Best Practice In Cardio-oncology

Developing ‘Best Practice’ in Cardio-oncology Cardiovascular toxicity has become a challenging issue during cancer therapy. A survey of oncologists in France reveals that respondents commonly (>90%) prescribe therapies that are associated with cardiotoxicity. interestingly, the survey shows that the assessment and management of the cardiovascular status of cancer patients is often inconsistent between oncologists before, during and after cancer therapy administration.

Heart of the Matter: Cardiac Toxicity

In 2002, Katharine Ray, a 27-year survivor of Hodgkin lymphoma, wanted work “that mattered” when she joined the staff of The Minnie Pearl Cancer Foundation (now PearlPoint Cancer Support) in Nashville, Tenn. A year later, at age 42, she received a diagnosis of stage 1 breast cancer, probably a result of radiation treatments she received when she was 14.


Principles for the Development of Cardio-Oncology Programs

  1. Detect CV toxicity (including vascular toxicity) in the most judicious and effective manner
  2. Describe the best clinical approaches to others
  3. Commit to training and education of medical professionals at all levels in order to refine the knowledge base.

All Things Cardio-Oncology

These podcasts are a timely resource for expanding your understanding of the growing field of Cardio-Oncology and all its dimensions


Utilizing Cardiac Biomarkers During Cancer Chemotherapy: How is this Actually Done?

Learn how Dr Lenihan utilizes readily available cardiac biomarkers to promote cardiac safety during cancer therapy

14 Oct 2021

17:00 BST